Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

• PubMed
Siegel RL, Miller KD, Wagle NS, Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.)| false
• Search Google Scholar
• Export Citation

Moyer VA, LeFevre ML, Siu AL, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.

• PubMed
Moyer VA, LeFevre ML, Siu AL, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.)| false
• Search Google Scholar
• Export Citation

Barocas DA, Mallin K, Graves AJ, et al. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 2015;194:1587–1593.

• PubMed
Barocas DA, Mallin K, Graves AJ, Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 2015;194:1587–1593.)| false
• Search Google Scholar
• Export Citation

Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416–2423.

• PubMed
Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416–2423.)| false
• Search Google Scholar
• Export Citation

Etzioni R, Gulati R. Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2016;2:955–956.

• PubMed
Etzioni R, Gulati R. Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA Oncol 2016;2:955–956.)| false
• Search Google Scholar
• Export Citation

Fedewa SA, Ward EM, Brawley O, et al. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 2017;177:1040–1042.

• PubMed
Fedewa SA, Ward EM, Brawley O, Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 2017;177:1040–1042.)| false
• Search Google Scholar
• Export Citation

Houston KA, King J, Li J, et al. Trends in prostate cancer incidence rates and prevalence of prostate specific antigen screening by socioeconomic status and regions in the Unites States, 2004 to 2013. J Urol 2018;199:676–682.

• PubMed
Houston KA, King J, Li J, Trends in prostate cancer incidence rates and prevalence of prostate specific antigen screening by socioeconomic status and regions in the Unites States, 2004 to 2013. J Urol 2018;199:676–682.)| false
• Search Google Scholar
• Export Citation

Kearns JT, Holt SK, Wright JL, et al. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 2018;124:2733–2739.

• PubMed
Kearns JT, Holt SK, Wright JL, PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 2018;124:2733–2739.)| false
• Search Google Scholar
• Export Citation

Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054–2061.

• PubMed
Jemal A, Fedewa SA, Ma J, Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054–2061.)| false
• Search Google Scholar
• Export Citation

Sammon JD, Abdollah F, Choueiri TK, et al. Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015;314:2077–2079.

• PubMed
Sammon JD, Abdollah F, Choueiri TK, Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015;314:2077–2079.)| false
• Search Google Scholar
• Export Citation

U.S. Preventative Services Task Force. Prostate cancer: screening. Accessed July 20, 2023. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

• PubMed
U.S. Preventative Services Task Force. Prostate cancer: screening. Accessed July 20, 2023. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening)| false
• Search Google Scholar
• Export Citation

Leapman MS, Wang R, Park H, et al. Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening. JAMA Oncol 2022;8:41–47.

• PubMed
Leapman MS, Wang R, Park H, Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening. JAMA Oncol 2022;8:41–47.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–360.

• PubMed
Fizazi K, Tran N, Fein L, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–360.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:686–700.

• PubMed
Fizazi K, Tran N, Fein L, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:686–700.)| false
• Search Google Scholar
• Export Citation

Chi KN, Protheroe A, Rodríguez-Antolín A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol 2018;19:194–206.

• PubMed
Chi KN, Protheroe A, Rodríguez-Antolín A, Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol 2018;19:194–206.)| false
• Search Google Scholar
• Export Citation

James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338–351.

• PubMed
James ND, de Bono JS, Spears MR, Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338–351.)| false
• Search Google Scholar
• Export Citation

Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018;36:1389–1395.

• PubMed
Szmulewitz RZ, Peer CJ, Ibraheem A, Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018;36:1389–1395.)| false
• Search Google Scholar
• Export Citation

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13–24.

• PubMed
Chi KN, Agarwal N, Bjartell A, Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13–24.)| false
• Search Google Scholar
• Export Citation

Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 2019;20:1518–1530.

• PubMed
Agarwal N, McQuarrie K, Bjartell A, Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 2019;20:1518–1530.)| false
• Search Google Scholar
• Export Citation

Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39:2294–2303.

• PubMed
Chi KN, Chowdhury S, Bjartell A, Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39:2294–2303.)| false
• Search Google Scholar
• Export Citation

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121–131.

• PubMed
Davis ID, Martin AJ, Stockler MR, Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381:121–131.)| false
• Search Google Scholar
• Export Citation

Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24:323–334.

• PubMed
Sweeney CJ, Martin AJ, Stockler MR, Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24:323–334.)| false
• Search Google Scholar
• Export Citation

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:2974–2986.

• PubMed
Armstrong AJ, Szmulewitz RZ, Petrylak DP, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:2974–2986.)| false
• Search Google Scholar
• Export Citation

Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40:1616–1622.

• PubMed
Armstrong AJ, Azad AA, Iguchi T, Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40:1616–1622.)| false
• Search Google Scholar
• Export Citation

James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–1177.

• PubMed
James ND, Sydes MR, Clarke NW, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–1177.)| false
• Search Google Scholar
• Export Citation

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–746.

• PubMed
Sweeney CJ, Chen YH, Carducci M, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–746.)| false
• Search Google Scholar
• Export Citation

Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–1087.

• PubMed
Kyriakopoulos CE, Chen YH, Carducci MA, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–1087.)| false
• Search Google Scholar
• Export Citation

Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–158.

• PubMed
Gravis G, Fizazi K, Joly F, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–158.)| false
• Search Google Scholar
• Export Citation

Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256–262.

• PubMed
Gravis G, Boher JM, Joly F, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256–262.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399:1695–1707.

• PubMed
Fizazi K, Foulon S, Carles J, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399:1695–1707.)| false
• Search Google Scholar
• Export Citation

Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132–1142.

• PubMed
Smith MR, Hussain M, Saad F, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132–1142.)| false
• Search Google Scholar
• Export Citation

Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–1159.

• PubMed
Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–1159.)| false
• Search Google Scholar
• Export Citation

Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918–2925.

• PubMed
Smith MR, Kabbinavar F, Saad F, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918–2925.)| false
• Search Google Scholar
• Export Citation

Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. Published online May 31, 2017. doi:10.1200/PO.17.00029

• PubMed
Abida W, Armenia J, Gopalan A, Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. Published online May 31, 2017. doi:10.1200/PO.17.00029)| false
• Search Google Scholar
• Export Citation

Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854–4861.

• PubMed
Ryan CJ, Shah S, Efstathiou E, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854–4861.)| false
• Search Google Scholar
• Export Citation

Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–1418.

• PubMed
Scher HI, Morris MJ, Stadler WM, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–1418.)| false
• Search Google Scholar
• Export Citation

Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217–227.

• PubMed
Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217–227.)| false
• Search Google Scholar
• Export Citation

Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–448.

• PubMed
Mohler JL, Gregory CW, Ford OH 3rd, The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–448.)| false
• Search Google Scholar
• Export Citation

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.

• PubMed
de Bono JS, Logothetis CJ, Molina A, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–992.

• PubMed
Fizazi K, Scher HI, Molina A, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–992.)| false
• Search Google Scholar
• Export Citation

Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13:1210–1217.

• PubMed
Logothetis CJ, Basch E, Molina A, Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13:1210–1217.)| false
• Search Google Scholar
• Export Citation

Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.

• PubMed
Ryan CJ, Smith MR, de Bono JS, Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.)| false
• Search Google Scholar
• Export Citation

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–160.

• PubMed
Ryan CJ, Smith MR, Fizazi K, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–160.)| false
• Search Google Scholar
• Export Citation

Hussaini A, Olszanski AJ, Stein CA, et al. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemother Pharmacol 2017;80:479–486.

• PubMed
Hussaini A, Olszanski AJ, Stein CA, Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemother Pharmacol 2017;80:479–486.)| false
• Search Google Scholar
• Export Citation

Goldwater R, Hussaini A, Bosch B, et al. Comparison of a novel formulation of abiraterone acetate vs the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet 2017;56:803–813.

• PubMed
Goldwater R, Hussaini A, Bosch B, Comparison of a novel formulation of abiraterone acetate vs the originator formulation in healthy male subjects: two randomized, open-label, crossover studies. Clin Pharmacokinet 2017;56:803–813.)| false
• Search Google Scholar
• Export Citation

Stein CA, Levin R, Given R, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs originator abiraterone acetate in patients with metastatic castration- resistant prostate cancer: the STAAR study. Urol Oncol 2018;36:81.e9–e16.

• PubMed
Stein CA, Levin R, Given R, Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs originator abiraterone acetate in patients with metastatic castration- resistant prostate cancer: the STAAR study. Urol Oncol 2018;36:81.e9–e16.)| false
• Search Google Scholar
• Export Citation

Romero-Laorden N, Lozano R, Jayaram A, et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration- resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018;119:1052–1059.

• PubMed
Romero-Laorden N, Lozano R, Jayaram A, Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration- resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 2018;119:1052–1059.)| false
• Search Google Scholar
• Export Citation

Fenioux C, Louvet C, Charton E, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019;123:300–306.

• PubMed
Fenioux C, Louvet C, Charton E, Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int 2019;123:300–306.)| false
• Search Google Scholar
• Export Citation

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–1197.

• PubMed
Scher HI, Fizazi K, Saad F, Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–1197.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration- resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147–1156.

• PubMed
Fizazi K, Scher HI, Miller K, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration- resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147–1156.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed August 1, 2023. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed August 1, 2023

• PubMed
U.S. Food & Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed August 1, 2023. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed August 1, 2023)| false
• Search Google Scholar
• Export Citation

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–433.

• PubMed
Beer TM, Armstrong AJ, Rathkopf DE, Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–433.)| false
• Search Google Scholar
• Export Citation

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017;71:151–154.

• PubMed
Beer TM, Armstrong AJ, Rathkopf DE, Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017;71:151–154.)| false
• Search Google Scholar
• Export Citation

Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 2016;17:153–163.

• PubMed
Shore ND, Chowdhury S, Villers A, Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 2016;17:153–163.)| false
• Search Google Scholar
• Export Citation

Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 2016;34:2098–2106.

• PubMed
Penson DF, Armstrong AJ, Concepcion R, Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 2016;34:2098–2106.)| false
• Search Google Scholar
• Export Citation

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378:2465–2474.

• PubMed
Hussain M, Fizazi K, Saad F, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378:2465–2474.)| false
• Search Google Scholar
• Export Citation

Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382:2197–2206.

• PubMed
Sternberg CN, Fizazi K, Saad F, Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382:2197–2206.)| false
• Search Google Scholar
• Export Citation

Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:556–569.

• PubMed
Tombal B, Saad F, Penson D, Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20:556–569.)| false
• Search Google Scholar
• Export Citation

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408–1418.

• PubMed
Smith MR, Saad F, Chowdhury S, Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378:1408–1418.)| false
• Search Google Scholar
• Export Citation

Saad F, Cella D, Basch E, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1404–1416.

• PubMed
Saad F, Cella D, Basch E, Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1404–1416.)| false
• Search Google Scholar
• Export Citation

Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79:150–158.

• PubMed
Smith MR, Saad F, Chowdhury S, Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79:150–158.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235–1246.

• PubMed
Fizazi K, Shore N, Tammela TL, Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380:1235–1246.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383:1040–1049.

• PubMed
Fizazi K, Shore N, Tammela TL, Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383:1040–1049.)| false
• Search Google Scholar
• Export Citation

Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025–1033.

• PubMed
Small EJ, Halabi S, Dawson NA, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025–1033.)| false
• Search Google Scholar
• Export Citation

Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908–913.

• PubMed
Dupont A, Gomez JL, Cusan L, Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908–913.)| false
• Search Google Scholar
• Export Citation

Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393–2400.

• PubMed
Sartor AO, Tangen CM, Hussain MH, Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393–2400.)| false
• Search Google Scholar
• Export Citation

Denmeade SR, Wang H, Agarwal N, et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol 2021;39:1371–1382.

• PubMed
Denmeade SR, Wang H, Agarwal N, TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J Clin Oncol 2021;39:1371–1382.)| false
• Search Google Scholar
• Export Citation

Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520.

• PubMed
Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520.)| false
• Search Google Scholar
• Export Citation

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.

• PubMed
Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.)| false
• Search Google Scholar
• Export Citation

Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–245.

• PubMed
Berthold DR, Pond GR, Soban F, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–245.)| false
• Search Google Scholar
• Export Citation

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117–124.

• PubMed
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117–124.)| false
• Search Google Scholar
• Export Citation

de Morrée ES, Vogelzang NJ, Petrylak DP, et al. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol 2017;3:68–75.

• PubMed
de Morrée ES, Vogelzang NJ, Petrylak DP, Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol 2017;3:68–75.)| false
• Search Google Scholar
• Export Citation

Lavaud P, Gravis G, Foulon S, et al. Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol 2018;73:696–703.

• PubMed
Lavaud P, Gravis G, Foulon S, Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol 2018;73:696–703.)| false
• Search Google Scholar
• Export Citation

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–1154.

• PubMed
de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–1154.)| false
• Search Google Scholar
• Export Citation

Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402–2408.

• PubMed
Bahl A, Oudard S, Tombal B, Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402–2408.)| false
• Search Google Scholar
• Export Citation

Meisel A, von Felten S, Vogt DR, et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 2016;56:93–100.

• PubMed
Meisel A, von Felten S, Vogt DR, Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 2016;56:93–100.)| false
• Search Google Scholar
• Export Citation

de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506–2518.

• PubMed
de Wit R, de Bono J, Sternberg CN, Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381:2506–2518.)| false
• Search Google Scholar
• Export Citation

Fizazi K, Kramer G, Eymard JC, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol 2020;21:1513–1525.

• PubMed
Fizazi K, Kramer G, Eymard JC, Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol 2020;21:1513–1525.)| false
• Search Google Scholar
• Export Citation

Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 2017;35:3198–3206.

• PubMed
Eisenberger M, Hardy-Bessard AC, Kim CS, Phase III study comparing a reduced dose of cabazitaxel (20 mg/m²) and the currently approved dose (25 mg/m²) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 2017;35:3198–3206.)| false
• Search Google Scholar
• Export Citation

Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 2017;35:3189–3197.

• PubMed
Oudard S, Fizazi K, Sengeløv L, Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 2017;35:3189–3197.)| false
• Search Google Scholar
• Export Citation

Sarantopoulos J, Mita AC, He A, et al. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose- escalation study. Cancer Chemother Pharmacol 2017;79:339–351.

• PubMed
Sarantopoulos J, Mita AC, He A, Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose- escalation study. Cancer Chemother Pharmacol 2017;79:339–351.)| false
• Search Google Scholar
• Export Citation

Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 2019;20:1432–1443.

• PubMed
Corn PG, Heath EI, Zurita A, Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 2019;20:1432–1443.)| false
• Search Google Scholar
• Export Citation

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.

• PubMed
Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.)| false
• Search Google Scholar
• Export Citation

Higano CS, Armstrong AJ, Sartor AO, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer 2019;125:4172–4180.

• PubMed
Higano CS, Armstrong AJ, Sartor AO, Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer 2019;125:4172–4180.)| false
• Search Google Scholar
• Export Citation

Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–52817.

• PubMed
Graff JN, Alumkal JJ, Drake CG, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–52817.)| false
• Search Google Scholar
• Export Citation

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–413.

• PubMed
Le DT, Durham JN, Smith KN, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–413.)| false
• Search Google Scholar
• Export Citation

Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29:1807–1813.

• PubMed
Hansen AR, Massard C, Ott PA, Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29:1807–1813.)| false
• Search Google Scholar
• Export Citation

Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 2019;5:471–478.

• PubMed
Abida W, Cheng ML, Armenia J, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 2019;5:471–478.)| false
• Search Google Scholar
• Export Citation

Tucker MD, Zhu J, Marin D, et al. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med 2019;8:4644–4655.

• PubMed
Tucker MD, Zhu J, Marin D, Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med 2019;8:4644–4655.)| false
• Search Google Scholar
• Export Citation

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.

• PubMed
Marabelle A, Le DT, Ascierto PA, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.)| false
• Search Google Scholar
• Export Citation

Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38:395–405.

• PubMed
Antonarakis ES, Piulats JM, Gross-Goupil M, Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38:395–405.)| false
• Search Google Scholar
• Export Citation

Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–1228.

• PubMed
Robinson D, Van Allen EM, Wu YM, Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–1228.)| false
• Search Google Scholar
• Export Citation

Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353–1365.

• PubMed
Marabelle A, Fakih M, Lopez J, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353–1365.)| false
• Search Google Scholar
• Export Citation

Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–1764.

• PubMed
Tannock IF, Osoba D, Stockler MR, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–1764.)| false
• Search Google Scholar
• Export Citation

Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506–2513.

• PubMed
Kantoff PW, Halabi S, Conaway M, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506–2513.)| false
• Search Google Scholar
• Export Citation

Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244–250.

• PubMed
Kaufman B, Shapira-Frommer R, Schmutzler RK, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244–250.)| false
• Search Google Scholar
• Export Citation